Dr. Soltero has over 40 years of pharmaceutical research and development experience. Prior to founding PharmaDirections in 2003, he was Executive Director of Pharmaceutical Development and Analytical Chemistry at Nobex Corporation where he led the strategic and project teams on oral insulin (licensed to GSK in 2002). Before that he was Vice President of Laboratory Operations at Magellan Laboratories (now Catalent) and at AAI. He has managed Analytical Chemistry, Organic Synthesis, Peptide Synthesis, Microbiology, and Biotechnology contract research laboratories. At AAI he was responsible for managing 300 staff in 8 labs with combined annual revenue of over $30MM.

Dr. Soltero has also managed ethical and OTC pharmaceutical R&D groups. SmithKline Beecham Consumer Healthcare employed him as their Worldwide Head of Analytical, Microbiology and Stability R&D. At Johnson & Johnson he was Manager of Pharmaceutical Analysis where he conducted biotechnology research and was a leader of the Platelet Derived Growth Factor project (now on the market as Regranex). At Berlex Laboratories he managed the Analytical R&D laboratory and the Pharmacy R&D formulation development programs. He joined Ciba-Geigy in 1967 where he held various positions of increasing responsibility from Formulation Technician to Senior Scientist/Supervisor in Biopharmaceutics and Preformulation Laboratories. He has over 45 scientific publications and presentations in the areas of biopharmaceutics, automation and protein product development. He is the primary inventor on 6 issued patents and on multiple patent applications in the areas of oral protein formulations, recombinant protein processes, drug delivery technologies, sustained release products, and electronic quality and manufacturing systems.